Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2026)

Stoke Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.9 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 85.67% year-over-year to $60.9 million; the TTM figure through Mar 2026 stood at $164.7 million (up 98.89% YoY), while the FY2025 annual figure was $136.6 million, up 127.63% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $60.9 million, up from $37.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $79.0 million in Q3 2022, with the low at $9.0 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $31.4 million (2024), against an average of $32.8 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments jumped 491.67% in 2023, then plunged 81.22% in 2024.
• Stoke Therapeutics' Change in Acquisitions & Divestments stood at $18.0 million in 2022, then fell by 16.8% to $15.0 million in 2023, then surged by 100.0% to $30.0 million in 2024, then climbed by 24.66% to $37.4 million in 2025, then soared by 62.84% to $60.9 million in 2026.
• Business Quant data shows STOK's Change in Acquisitions & Divestments at $60.9 million in Q1 2026, $37.4 million in Q4 2025, and $33.2 million in Q3 2025.